Psychiatric Manifestations in Patients with Biopterin Defects

Abstract

Psychiatric manifestations in patients with tetrahydrobiopterin (BH4) defects are common, and may occur even with treatment of the underlying disorder. The neurobiological background of these conditions has been linked to abnormalities of neurotransmitters, such as dopamine, serotonin, norepinephrine, and gamma-aminobutyric acid. Here, we review the psychiatric profile of all patients with BH4 defects followed in the pediatric and adult metabolic clinics at our center. Three patients with autosomal recessive (AR) guanosine triphosphate cyclohydrolase (GTPCH) deficiency and three patients with 6-pyruvoyl tetrahydropterin synthase (PTPS) deficiency were reviewed.

All patients had behavioral disturbances and two had significant psychiatric comorbidities. These included attention deficit/hyperactivity disorder, anxiety, depression, aggression, or oppositional defiant disorder. One patient with PTPS deficiency had a severe psychiatric presentation, requiring inpatient admission and temporary placement into foster care for intensive behavioral therapy. Another with AR GTPCH deficiency was diagnosed with aggressive behavioral dysregulation requiring intensive psychiatric treatment. Management of the psychiatric manifestations of BH4 defects can be challenging, due to lack of information and studies of interactions between psychiatric medications on the deficient neurotransmitters and their receptors in these conditions. Further studies are needed to establish safety and efficacy of these treatments.

Keywords

inherited neurotransmitter disorders - tetrahydrobiopterin - levodopa/carbidopa

Note

Previously presented at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM). Rotterdam, Netherlands. September 3-4, 2019.

Publikationsverlauf

Eingereicht: 18. Juli 2021

Angenommen: 11. Dezember 2021

Artikel online veröffentlicht:
28. Januar 2022

• References

• 1 Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis 2009; 32 (03) 333-342
• 2 Kurian MA, Gissen P, Smith M, Heales Jr S, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011; 10 (08) 721-733
• 3 Ng J, Papandreou A, Heales SJ, Kurian MA. Monoamine neurotransmitter disorders–clinical advances and future perspectives. Nat Rev Neurol 2015; 11 (10) 567-584
• 4 Pan L, McKain BW, Madan-Khetarpal S. et al. GTP-cyclohydrolase deficiency responsive to sapropterin and 5-HTP supplementation: relief of treatment-refractory depression and suicidal behaviour. BMJ Case Rep 2011; 2011: bcr0320113927
• 5 Van Hove JL, Steyaert J, Matthijs G. et al. Expanded motor and psychiatric phenotype in autosomal dominant Segawa syndrome due to GTP cyclohydrolase deficiency. J Neurol Neurosurg Psychiatry 2006; 77 (01) 18-23
• 6 Latorre A, Salgado P, Salari M, Jesuthasan A, Bhatia KP. Combined dystonia with self-mutilation in 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency: a case report. Mov Disord Clin Pract (Hoboken) 2018; 6 (01) 81-82
• 7 Roze E, Vidailhet M, Blau N. et al. Long-term follow-up and adult outcome of 6-pyruvoyl-tetrahydropterin synthase deficiency. Mov Disord 2006; 21 (02) 263-266
• 8 Wang L, Yu W-M, He C. et al. Long-term outcome and neuroradiological findings of 31 patients with 6-pyruvoyltetrahydropterin synthase deficiency. J Inherit Metab Dis 2006; 29 (01) 127-134
• 9 Leuzzi V, Carducci CA, Carducci CL. et al. Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency. Clin Genet 2010; 77 (03) 249-257
• 10 Derwińska K, Mierzewska H, Goszczańska A. et al. Clinical improvement of the aggressive neurobehavioral phenotype in a patient with a deletion of PITX3 and the absence of L-DOPA in the cerebrospinal fluid. Am J Med Genet B Neuropsychiatr Genet 2012; 159B [phone]
• 11 Horvath GA, Tarailo-Graovac M, Bartel T. et al. Improvement of self-injury with dopamine and serotonin replacement therapy in a patient with a hemizygous PAK3 mutation: a new therapeutic strategy for neuropsychiatric features of an intellectual disability syndrome. J Child Neurol 2018; 33 (01) 106-113
• 12 Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122 (05) 509-522
• 13 Asberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann N Y Acad Sci 1997; 836: 158-181
• 14 van Erp AMM, Miczek KA. Aggressive behavior, increased accumbal dopamine, and decreased cortical serotonin in rats. J Neurosci 2000; 20 (24) 9320-9325
• 15 Moore TM, Scarpa A, Raine A. A meta-analysis of serotonin metabolite 5-HIAA and antisocial behavior. Aggress Behav 2002; 28 (04) 299-316
• 16 Seo D, Patrick CJ, Kennealy PJ. Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Behav 2008; 13 (05) 383-395
• 17 Mauri MC, Paletta S, Maffini M. et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 2014; 13: 1163-1191
• 18 Swann AC. Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry 2003; 64 (Suppl. 04) 26-35
• 19 Comai S, Tau M, Pavlovic Z, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol 2012; 32 (02) 237-260
• 20 Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology 2009; 57 (7-8): 579-589
• 21 Dela Peña I, Gevorkiana R, Shi W-X. Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms. Eur J Pharmacol 2015; 764: 562-570
• 22 Kvernmo T, Härtter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28 (08) 1065-1078
• 23 Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord 2009; 24 (01) 129-133
• 24 Kurlan R, Crespi G, Coffey B, Mueller-Vahl K, Koval S, Wunderlich G. Pramipexole for TS Trial Investigators. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. Mov Disord 2012; 27 (06) 775-778
• 25 Newcorn JH, Schulz K, Harrison M, DeBellis MD, Udarbe JK, Halperin JM. Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am 1998; 45 (05) 1099-22 , viii -viii
• 26 Opladen T, López-Laso E, Cortès-Saladelafont E. et al; International Working Group on Neurotransmitter related Disorders (iNTD). Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH₄) deficiencies. Orphanet J Rare Dis 2020; 15 (01) 126